None

Axicabtagene Ciloleucel is a CAR-T cell therapy used to treat specific types of B cell lymphoma, especially patients with relapsed or refractory large B cell lymphoma.

1. Indications:

Aquilenza is mainly used to treat the following two types of adult patients:

Relapsed or refractory large cell lymphomaB cell lymphoma

Primary anaplastic macrophageBcell lymphoma

2. Mechanism of action:

Akilenza is a CAR-T (chimeric antigen receptorT cell) therapy. It works through the following steps:

Extract the patient'sT cells.

These T cells are genetically engineered, and the CAR guide receptor is introduced into the T cells so that they can recognize the CD19 antigen.

The expandedCAR-T cells are reinjected into the patient.

CAR-T cells can locate and destroy CD19 antigen-expressing cancer cells.

3. Pharmacology:

The pharmacology of Aquilenza mainly involvesCAR-TThe process of production, expansion, localization and killing of tumor cells. It initiates an immune response in the body that helps patients fight lymphoma.

4. Dosage and usage:

The dosage and usage of Akilenza should be determined by a medical professional based on the patient's specific condition. Typically, it is given to patients via intravenous injection. Some preparation is usually required before treatment, including preparing the patient's Tcells.

5. Side effects:

Akironza may cause a series of side effects, including but not limited to: fever, chills, headache, nausea, leukopenia, anemia, thrombocytopenia, shortness of breath, hypotension, rash, itching, lymphocytosis, acute kidney injury, etc.

6. Warnings and Precautions:

Doctors and patients should pay special attention to the following when using Aquilenza:

Closely monitor side effects and take timely measures.

Patients may require long-term medical monitoring and follow-up.

Akilenza can cause severe immune reactions, and doctors need to be prepared to manage these situations.

Patients need to avoid vaccinations while receiving treatment.

7. Contraindications:

There are currently no clear contraindications, but a patient's specific circumstances may affect whether they can receive Aquilenza treatment. Doctors will consider the patient's overall health to decide whether this treatment is appropriate.

8. Drug interactions:

The interactions of Akilenza with other drugs are unknown, so careful consideration is needed when using other drugs to avoid unnecessary risks.

9. Drugs for special groups:

Aquilenza is mainly used for adult patients and is generally not suitable for children. For special groups, such as pregnant or lactating women, it should be used with caution, and the decision whether to receive treatment must be made under the guidance of a doctor.

In summary, Akilenza is a revolutionary CAR-T cell therapy for the treatment of certain types of large B cell lymphoma. Although it has significant therapeutic potential, both patients and physicians need to understand its indications, mechanism of action, dosage, side effects, and precautions to ensure safe and effective use of this therapy. Ultimately, treatment decisions should be made by medical professionals based on the patient's specific circumstances.